Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefits

Paul J Bröckelmann^{1

2

3

4}, Peter Borchmann^{1

2}

Affiliations

¹ Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne, Germany.
² German Hodgkin Study Group (GHSG), Cologne, Germany.
³ Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Cologne, Germany.
⁴ Max Planck Research Group Mechanisms of DNA Repair, Max Planck Institute for Biology of Ageing, Cologne, Germany.

Paul J Bröckelmann et al. Br J Haematol. 2022 Jun.

. 2022 Jun;197(5):515-517.

doi: 10.1111/bjh.18130. Epub 2022 Mar 9.

Paul J Bröckelmann^{1

2

3

4}, Peter Borchmann^{1

2}

¹ Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne, Germany.
² German Hodgkin Study Group (GHSG), Cologne, Germany.
³ Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Cologne, Germany.
⁴ Max Planck Research Group Mechanisms of DNA Repair, Max Planck Institute for Biology of Ageing, Cologne, Germany.

No abstract available

References

1. Aleman BM, van den AW B-D, Klokman WJ, MB V't V, Bartelink H, van FE L. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21:3431-9.
1. Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015;373:2499-511.
1. Follows GA, Barrington SF, Bhuller KS, Culligan DJ, Cutter DJ, Gallop-Evans E, et al. Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline. Br J Haematol. 2022;197:558-572.
1. Sasse S, Brockelmann PJ, Goergen H, Plutschow A, Muller H, Kreissl S, et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017;35:1999-2007.
1. Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J Clin Oncol. 2019;37:2825-45.